BPA
UTHR icon

Beacon Pointe Advisors’s United Therapeutics UTHR Stock Holding History

Beacon Pointe Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
2,389
-28
-1% -$15.8K 0.01% 927
2026
Q1 		$1.43M Buy
2,417
+215
+10% +$107K 0.01% 857
2025
Q4 		$1.07M Buy
2,202
+3
+0.1% +$1.4K 0.01% 815
2025
Q3 		$922K Buy
+2,199
New +$740K 0.01% 784

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Beacon Pointe Advisors's UTHR Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its United Therapeutics (UTHR) stake by 1.2% in Q2 2026, selling an estimated $15.8K and leaving 2,389 shares worth $1.29M. The position accounts for 0.01% of the portfolio, ranked #927.

Beacon Pointe Advisors first reported a position in UTHR in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.43M in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Beacon Pointe Advisors held 2,389 shares of United Therapeutics worth $1.29M as of Q2 2026.
  • Beacon Pointe Advisors sold 28 United Therapeutics shares in Q2 2026, an estimated $15.8K.
  • United Therapeutics made up 0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #927 holding.
  • Beacon Pointe Advisors first reported a position in United Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Beacon Pointe Advisors's United Therapeutics position peaked at $1.43M in Q1 2026.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.